Empowering living medicines.
Encellin is focused on advancing next generation therapies, starting with endocrine disorders.
The cell is the original smart machine. All drugs, devices, and even digital health approaches are trying to mirror cellular functions.
Encellin has developed an Encapsulated Cell Replacement Therapy (EnCRT), that helps these cells survive in the body. Encellin’s EnCRT allows enclosed cells to function like smart molecular factories, releasing therapeutics when needed.
THE PROBLEM
Cells play complex roles to ensure our health and safety. When cells are missing, damaged or diseased, the body cannot function correctly.
OUR SOLUTION
EnCRT, A minimally invasive implant delivering therapeutics where needed.
Encellin’s technology and patient-driven approach combines a novel cell encapsulation technology with functional cell therapies to treat chronic diseases, starting with endocrine disorders.
Starting with: Endocrine Disorders
Encellin’s initial pipeline focuses on endocrine disorders with a clear mechanism of action. The company’s lead programs focus on Hypoglycemia, the highest unmet clinical need in type 1 diabetes. The platform is focused on leveraging the power of cells to deliver years of sophisticated therapies with a single implant.
